Center for Medicine in the Public Interest

Last updated
Center for Medicine in the Public Interest
AbbreviationCMPI
Typenon-profit medical issues research group think tank
Headquarters New York City, United States
Key people
  • Robert Goldberg
  • Gad Berdugo
  • Fred Goodwin
  • Steven Sammut
  • Michael Tew
  • Mark Thornton
  • Michael Weber
Revenue (2014)
$353,000 [1]
Expenses (2014)$373,744 [1]
Website cmpi.org

The Center for Medicine in the Public Interest (CMPI) is a non-profit medical issues research group. [2] It was founded by the "free-market think tank" Pacific Research Institute. [3] CMPI's research agenda deals with clinical outcomes and econometric studies that analyze the value of new medicines and genomic and molecular-based medical innovation.

Contents

CMPI is a 501(c)(3) organization and as such is not permitted to devote a substantial part of its activity to lobbying. Its officers have written articles on various issues including price controls on pharmaceutical products in publicly funded healthcare schemes in the United States, [4] and restrictions on advertising in the European Union. [5] The Economist Intelligence Unit has written that the organisation generally takes a pro-drug industry viewpoint. [6]

Issues

Universal healthcare

CMMPI is a strong opponent of universal healthcare and favors a free-market approach to health care policy. The center created a website called BigGovHealth.org to tell the stories of people who faced difficulties with the health care systems in Europe and Canada. The site also included interviews with health policy experts in Europe and Canada. The website is no longer up, now showing a page where you can offer to purchase the domain. [7] [8]

Drug imports

The group opposes the importation of drugs in order to lower prices in the United States, arguing in part that Canadian pharmaceutical companies' products are dangerous because they are not regulated by the FDA but by foreign government agencies. [9]

Personnel

CMPI was founded by Peter Pitts, former FDA Associate Commissioner for External Relations under the Bush administration, and Dr. Robert Goldberg, former fellow at the Manhattan Institute. [10]

CMPI Senior Fellows include:

Funding

Funders include PhRMA and Pfizer. [11]

Reports

CMPI has published studies on the value of new cancer drugs, the cost-effectiveness of certain Alzheimer's treatments, evidence-based medicine, and drug counterfeiting. [12]

Related Research Articles

<span class="mw-page-title-main">Food and Drug Administration</span> United States federal agency

The United States Food and Drug Administration is a federal agency of the Department of Health and Human Services. The FDA is responsible for protecting and promoting public health through the control and supervision of food safety, tobacco products, caffeine products, dietary supplements, prescription and over-the-counter pharmaceutical drugs (medications), vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices (ERED), cosmetics, animal foods & feed and veterinary products.

<span class="mw-page-title-main">Sildenafil</span> Drug for erectile dysfunction and hypertension

Sildenafil, sold under the brand name Viagra, among others, is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is also sometimes used off-label for the treatment of certain symptoms in secondary Raynaud's phenomenon. It is unclear if it is effective for treating sexual dysfunction in women. It can be taken orally, intravenously, or sublingually. Onset when taken orally is typically within twenty minutes and lasts for about two hours.

<span class="mw-page-title-main">Pfizer</span> American multinational pharmaceutical and biotechnology corporation

<span class="mw-page-title-main">Generic drug</span> Pharmaceutical equivalent to a brand-name product

A generic drug is a pharmaceutical drug that contains the same chemical substance as a drug that was originally protected by chemical patents. Generic drugs are allowed for sale after the patents on the original drugs expire. Because the active chemical substance is the same, the medical profile of generics is equivalent in performance compared to their performance at the time when they were patented drugs. A generic drug has the same active pharmaceutical ingredient (API) as the original, but it may differ in some characteristics such as the manufacturing process, formulation, excipients, color, taste, and packaging.

Prescription drug list prices in the United States continually rank among the highest in the world. The high cost of prescription drugs became a major topic of discussion in the 21st century, leading up to the American health care reform debate of 2009, and received renewed attention in 2015. One major reason for high prescription drug prices in the United States relative to other countries is the inability of government-granted monopolies in the American health care sector to use their bargaining power to negotiate lower prices, and the American payer ends up subsidizing the world's R&D spending on drugs.

<span class="mw-page-title-main">Prescription drug</span> Medication legally requiring a medical prescription before it can be dispensed

A prescription drug is a pharmaceutical drug that is permitted to be dispensed only to those with a medical prescription. In contrast, over-the-counter drugs can be obtained without a prescription. The reason for this difference in substance control is the potential scope of misuse, from drug abuse to practicing medicine without a license and without sufficient education. Different jurisdictions have different definitions of what constitutes a prescription drug.

Single-payer healthcare is a type of universal healthcare in which the costs of essential healthcare for all residents are covered by a single public system.

Pharmacovigilance, also known as drug safety, is the pharmaceutical science relating to the "collection, detection, assessment, monitoring, and prevention" of adverse effects with pharmaceutical products. The etymological roots for the word "pharmacovigilance" are: pharmakon and vigilare. As such, pharmacovigilance heavily focuses on adverse drug reactions (ADR), which are defined as any response to a drug which is noxious and unintended, including lack of efficacy. Medication errors such as overdose, and misuse and abuse of a drug as well as drug exposure during pregnancy and breastfeeding, are also of interest, even without an adverse event, because they may result in an adverse drug reaction.

<span class="mw-page-title-main">Sibutramine</span> Chemical compound used in the treatment of obesity in some countries

Sibutramine, formerly sold under the brand name Meridia among others, is an appetite suppressant which has been discontinued in many countries. It works as a serotonin–norepinephrine reuptake inhibitor similar to a tricyclic antidepressant. Until 2010, it was widely marketed and prescribed as an adjunct in the treatment of obesity along with diet and exercise. It has been associated with increased cardiovascular diseases and strokes and has been withdrawn from the market in 2010 in several countries and regions including Australia, Canada, China, the European Union, Hong Kong, India, Mexico, New Zealand, the Philippines, Thailand, the United Kingdom, and the United States. However, the drug remains available in some countries.

An online pharmacy, internet pharmacy, or mail-order pharmacy is a pharmacy that operates over the Internet and sends orders to customers through mail, shipping companies, or online pharmacy web portal.

A Patient Safety Organization (PSO) is a group, institution, or association that improves medical care by reducing medical errors. Common functions of patient safety organizations are data collection, analysis, reporting, education, funding, and advocacy. A PSO differs from a Federally designed Patient Safety Organization (PSO), which provides health care providers in the U.S. privilege and confidentiality protections for efforts to improve patient safety and the quality of patient care delivery

<span class="mw-page-title-main">Healthcare in Iran</span>

For health issues in Iran see Health in Iran.

In medicine, an indication is a valid reason to use a certain test, medication, procedure, or surgery. There can be multiple indications to use a procedure or medication. An indication can commonly be confused with the term diagnosis. A diagnosis is the assessment that a particular [medical] condition is present while an indication is a reason for use. The opposite of an indication is a contraindication, a reason to withhold a certain medical treatment because the risks of treatment clearly outweigh the benefits.

<span class="mw-page-title-main">Health policy</span> Policy area that deals with the health system of a country or other organization

Health policy can be defined as the "decisions, plans, and actions that are undertaken to achieve specific healthcare goals within a society". According to the World Health Organization, an explicit health policy can achieve several things: it defines a vision for the future; it outlines priorities and the expected roles of different groups; and it builds consensus and informs people.

A counterfeit medication or a counterfeit drug is a medication or pharmaceutical item which is produced and sold with the intent to deceptively represent its origin, authenticity, or effectiveness. A counterfeit drug may contain inappropriate quantities of active ingredients, or none, may be improperly processed within the body, may contain ingredients that are not on the label, or may be supplied with inaccurate or fake packaging and labeling. Counterfeit drugs are related to pharma fraud. Drug manufacturers and distributors are increasingly investing in countermeasures, such as traceability and authentication technologies, to try to minimise the impact of counterfeit drugs. Antibiotics with insufficient quantities of an active ingredient add to the problem of antibiotic resistance.

<span class="mw-page-title-main">Ministry of Health and Medical Education</span>

Healthcare in the United States is largely provided by private sector healthcare facilities, and paid for by a combination of public programs, private insurance, and out-of-pocket payments. The U.S. is the only developed country without a system of universal healthcare, and a significant proportion of its population lacks health insurance.

Specialty drugs or specialty pharmaceuticals are a recent designation of pharmaceuticals classified as high-cost, high complexity and/or high touch. Specialty drugs are often biologics—"drugs derived from living cells" that are injectable or infused. They are used to treat complex or rare chronic conditions such as cancer, rheumatoid arthritis, hemophilia, H.I.V. psoriasis, inflammatory bowel disease and hepatitis C. In 1990 there were 10 specialty drugs on the market, around five years later nearly 30, by 2008 200, and by 2015 300.

The distribution of medications has special drug safety and security considerations. Some drugs require cold chain management in their distribution.

A first-in-class medication is a pharmaceutical that uses a "new and unique mechanism of action" to treat a particular medical condition. While the Food and Drug Administration's Center for Drug Evaluation and Research tracks first-in-class medications and reports on them annually, first-in-class is not considered a regulatory category. Although many first-in-class medications qualify as breakthrough therapies, Regenerative Medicine Advanced Therapies and/or orphan drugs, first-in-class status itself has no regulatory effect.

References

  1. 1 2 "Center for Medicine in the Public Interest" (PDF). Foundation Center. Retrieved 23 March 2017.
  2. Herper, Matthew (2007-07-25). "The Nissen Doctrine". Forbes. Archived from the original on March 11, 2008. Retrieved 2008-01-14.
  3. Lee Fang (Nov 18, 2009). "Exclusive: Attacks On Health Reform Orchestrated By Yet Another Shadowy Corporate Front Group — 'CMPI'". Center for American Progress . Retrieved 19 November 2009.
  4. Goldberg, Robert (2006-12-25). "HillaryCare Comes Back". The Weekly Standard. News America Incorporated. Retrieved 2008-01-14.
  5. Pitts, Peter J. (2006-04-12). "Power to the Patients". The Wall Street Journal . Retrieved 2008-01-14.
  6. "USA healthcare: FDA centenary prompts politicking". Economist Intelligence Unit. Economist Group. 2006-07-05. Retrieved 2008-01-14.
  7. "Home". biggovhealth.com.
  8. "Site attacks single-payer health care - POLITICO". Politico .
  9. "Proposed drug importation bill would expose Americans to counterfeit meds". 23 January 2019.
  10. Jason Lee Miller (2008-08-01). "Are Google Results Hazardous To Your Health?". WebProNews. iEntry, Inc. Archived from the original on 2008-01-12. Retrieved 2008-01-14.
  11. "Site attacks single-payer health care - POLITICO". Politico .
  12. Laurie Sullivan (2006-06-13). "Pharmaceuticals Slowly Adopting RFID To Protect Prescription Drug Supplies". Information Week. CMP Media LLC. Retrieved 2008-01-14.